RxDoctor Payments Data

Aleksandr Gazarov, MD

Psychiatry · Santa Teresa, NMNPI 1932282225

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 25.1% of the total.

$982in general payments, 2019–2025

Across 45 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$246
  • Takeda Pharmaceuticals U.S.A., Inc.$233
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$181
  • Otsuka America Pharmaceutical, Inc.$152
  • Alkermes, Inc.$119
  • Johnson & Johnson$29
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$982 in reported general payments places this provider in the 80th percentile of 174 psychiatry providers in New Mexico.

See all psychiatry providers in New Mexico

Medicare billing

Part B allowed, 2024
$75,755
Medicare patients
88
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$94,313
Abilify MaintenaAripiprazole17$61,647
NuedextaDextromethorphan Hbr/Quinidine13$25,731
CaplytaLumateperone Tosylate11$17,554
SavellaMilnacipran Hcl16$12,570
ViibrydVilazodone Hcl31$11,177
Aripiprazole194$9,065
Desvenlafaxine Succinate ErDesvenlafaxine Succinate151$9,043
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$8,974
Quetiapine Fumarate470$5,705
Oxcarbazepine76$5,365
Lurasidone Hcl46$3,947
Clonazepam321$3,808
Ziprasidone Hcl101$3,340
Benztropine Mesylate156$2,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$152$61,64717 claims
AbbVieSavella, Viibryd$246$23,74847 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$181$17,55411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 174 psychiatry providers in New Mexico.

Other psychiatry in Santa Teresa

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →